




Amarin Corporation plc  
Investor Relations Department  
2 Pembroke House, Upper  
Pembroke  
Street 28-32  
Dublin 2  
Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: AMRN**

Last Trade:	3.04
Trade Time:	4:00 PM ET Aug 22, 2017
Change:	0.01  (+0.330%)
Day Range	2.97 - 3.05
52-Week Range	2.56 - 4.47
Volume	1,179,233

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Aug 14, 2017*

[Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee](#)

*Aug 2, 2017*

[Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations](#)

*Jul 26, 2017*

[Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017](#)

*Jun 12, 2017*

[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides](#)

*Jun 1, 2017*

[Amarin to Present at the Jefferies 2017 Global Healthcare Conference](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

*Mar 1, 2017*

[Annual Report \(10-K\)](#)

*Apr 21, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Aug 2, 2017*

[Quarterly Report \(10-Q\)](#)

*May 3, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 3, 2016*

[Quarterly Report \(10-Q\)](#)